June 6, 2012 in Medical (E)
[prMac.com] Severna Park, MD - Severna Park, MD - Medical technology company, iSonea Ltd. (ASX: ISN; OTCQX: ISOAY) today announced the launch of a new asthma management smartphone app, AsthmaSense(TM), available for iPhone, iPad and Android users. AsthmaSense is the most comprehensive, yet easy-to-use smartphone app designed specifically to help improve the way people live with and manage asthma.
AsthmaSense is the first app to bring together everything you need to manage asthma more effectively and conveniently. Once you program your asthma action plan, AsthmaSense makes sure you are tracking to your plan with active reminders. The AsthmaSense app allows you to record and track your symptoms, lung function tests, asthma events, and medications. It also provides interactive medication and testing reminders.
* Journal: Easily record peak flow, wheeze, medication use (scheduled, unscheduled and missed medication dosages) and symptoms
* Alerts: Set the tone and time for medication and testing reminders. Receive alerts when your asthma is "not well controlled" or "poorly controlled" according to medical community guidelines
* Rescue: access emergency contact information quickly and easily
* Manage your data: Review up to two months of medication use. Share your AsthmaSense data with a physician, family member or caregiver
In the United States alone, 25 million people have asthma, according to the Centers for Disease Control (CDC). The CDC also estimates the cost burden in the U.S. alone exceeds $56 billion annually, as poorly controlled asthma is associated with increased emergency room visits, hospitalizations and medical costs. The World Health Organization estimates that there are more than 250,000 deaths globally from poorly controlled asthma every year. The medical community's guidelines, including those from the Global Initiative for Asthma (GINA) and the National Heart, Lung, and Blood Institute (NHLBI), state that regular monitoring of breathing symptoms is necessary to improve medication compliance and successful long-term management of asthma. It is also recommended that all people with asthma have an asthma action plan developed with their doctor to help control their asthma.
"Managing asthma is crucial to controlling the disease and improving health; however regular, diligent monitoring of symptoms, triggers and medications can be challenging for patients, caregivers and parents alike," said Lynn M. Taussig, M.D., Chairman of iSonea's Medical Advisory Board, Special Advisor to the Provost for the Life Sciences at the University of Denver and the retired president and CEO of National Jewish Medical and Research Center. "AsthmaSense smartphone app is an easy and convenient way to monitor and track asthma and keep your doctor informed of your condition and progress. This ultimately leads to better health, avoids emergency visits and provides peace of mind for patients and their families."
"iSonea is dedicated to developing innovative, easy-to-use devices and mobile apps that help improve asthma monitoring and management," said Michael Thomas, CEO of iSonea Ltd. "We built the AsthmaSense app with the user in mind. We understand how critical it is to track your asthma, and so we built an app with key features that help you better manage your asthma anywhere, anytime.
AsthmaSense is available for purchase at the Apple App Store (for iPhone and iPad users) and Google Play and Amazon App Stores (for Android users). The app has a one-time cost of $3.99. Future versions of AsthmaSense will incorporate iSonea's WheezoMeter(R) which uses the company's Acoustic Respiratory Monitoring (ARM(TM)) to measure wheezing, one of the principal symptoms of asthma. In future versions, the company plans to support other operating platforms and incorporate features such as a sensor that detects changes in environmental conditions such as air quality and weather.
Forward Looking Statements:
Certain statements made in this announcement are forward-looking statements. These forward looking statements are not historical facts but rather are based on iSonea's current expectations, estimates and projections about the industry in which iSonea operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "guidance" and similar expressions are intended to identify forward-looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of iSonea, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. iSonea cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of iSonea only as of the date of this release. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. iSonea will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.
* 3/4G iPhone, iPad, or 3/4G iPod touch
* Requires iOS 5.0 or later
* 3.0 MB
Pricing and Availability:
AsthmaSense 1.0 is $3.99 USD (or equivalent amount in other currencies) and available worldwide exclusively through the App Store in the Medical category.
iSonea Limited (ASX:ISN; OTCQX:ISOAY) is an emerging medical technology company developing innovative, non-invasive devices and mobile health apps to improve the management of chronic, costly respiratory disorders such as asthma and COPD. By leveraging iSonea's proprietary Acoustic Respiratory Monitoring(TM) (ARM) technology with its AsthmaSense(TM) mobile applications, iSonea is turning smartphones into medical devices - enabling anyone, anywhere, at any time to monitor breathing distress symptoms, in order to take action. iSonea's ARM devices have been cleared for use by the U.S. Food and Drug Administration, the Australian TGA and the European Union CE. Copyright (C) 2012 iSonea Limited. All Rights Reserved. Apple, the Apple logo, iPhone, iPod and iPad are registered trademarks of Apple Inc. in the U.S. and/or other countries.